Navigation Links
INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder
Date:7/31/2009

ion to reduce to 9 mg. In addition to study medication, subjects were permitted to receive concomitant treatment with a mood stabilizer and/or antidepressant, provided these medications had been given at a stable dose within 30 days of screening. Approximately half the subjects enrolled received ongoing treatment with a mood stabilizer and/or antidepressant during the studies. The most commonly used mood stabilizers were valproate and lithium. The most commonly used antidepressants were SSRIs and SNRIs.

Efficacy was evaluated using the positive and negative symptom scale (PANSS), a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression. As secondary outcomes, mood symptoms were evaluated using the Hamilton Depression Rating Scale (HAM-D-21) and the Young Mania Rating Scale (YMRS).

The INVEGA(R) group in the flexible-dose study (dosed between 3 and 12 mg/day, mean modal dose of 8.6 mg/day) and the higher dose group of INVEGA(R) in the 2 dose-level study (12 mg/day with option to reduce to 9 mg/day) were each superior to placebo in the PANSS. Numerical improvements in mood symptoms were also observed, as measured by the HAM-D-21 and YMRS. In the lower dose group of the 2 dose-level study (6 mg/day with option to reduce to 3 mg/day), INVEGA(R) was not significantly different from placebo as measured by the PANSS.

The most common adverse events (incidence greater than or equal to 5% and at least twice that for placebo) were extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increase, and nasopharyngitis.

"Schizoaffective disorder is a chronic, disabling condition," said Husseini Manji, M.D., F.R.C.P.C., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Pharmaceutical Research & Development. "This new indication for INVEGA(R) fur
'/>"/>

SOURCE Janssen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. $52.5 Million Settlement Against Sepracor Inc. Approved
2. FDA Cracks Down on Unapproved Cough Medicines
3. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
4. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
5. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
6. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
7. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
8. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
9. Pennsylvania American Waters Rate Case Approved
10. RNs Statement on Death of Nataline Sarkisyan: CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago
11. Hiemstra Approved to Manufacture Medical Devices in New CER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... The Wm. Jennings Bryan Dorn Veterans Affairs ... hall meeting for Veterans and their families on September 24. ... to provide Veterans with valuable healthcare and benefit information,” said ... provide a forum where we can gather important input directly ... fair will be held 4:45 p.m. to 5:45 p.m. in ...
(Date:9/2/2014)... California, the percentage undergoing a double mastectomy increased substantially ... associated with a lower risk of death than breast-conserving ... September 3 issue of JAMA . The authors ... breast was associated with a higher risk of death ... Randomized trials have demonstrated similar survival for patients with ...
(Date:9/2/2014)... September 02, 2014 Medex Analytic ... of their corporate headquarters in Coral Springs, Fla. due ... exceeded our business development objectives for the 2014 year ... Herbst. “Our industry has requested a higher level of ... reviews. Medex has delivered, and the industry has responded.” ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Two new studies further confirm ... 6-year-olds who were breast-fed have a lower risk of ... while the other finds a similar trend when it ... benefits of breast-feeding in the immediate newborn period," said ... in New York City. She was not involved in ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... ... based on scientific evidence, including toxins such as pesticides, and provides proven natural treatments ... ... new book on ADHD by Dr. Sanford Newmark, one of America’s leading integrative pediatricians, ...
... solace in talks with partners and friends, researchers found , WEDNESDAY, ... found that it,s a good idea for men to confide to ... unhappiness -- but the same was not necessarily true for women. ... 861 people aged 57 to 85. They all had sexual partners ...
... likely to develop problem , WEDNESDAY, May 19 (HealthDay ... other similar medications, may prompt long-term hearing loss among ... 18 issue of the Archives of Otolaryngology -- ... of Alabama at Birmingham discuss evidence supporting an association ...
... ... by Health Savings Account (HSA)-eligible insurance plans, an increase of 25 percent since last ... , ... May 19, 2010 -- Ten million Americans are covered by Health Savings Account (HSA)-eligible ...
... ... , ... -- Can companies generate leads and sales from social media? That’s the number one question ... , A new report from Zuberance shows that companies are making their cash registers ...
... have analysed the presence of voice disorders in male and ... of the Early Childhood and Primary Education teaching body suffer ... Professions such as teaching require a high resistance ... overload. "Our aim was to analyse the vocal problems of ...
Cached Medicine News:Health News:Book Delivers Latest ADHD Research, Treatments & Results 2Health News:Book Delivers Latest ADHD Research, Treatments & Results 3Health News:Confiding Eases Older Men's Stress Over Sexual Problems 2Health News:Viagra Linked to Hearing Loss 2Health News:Health Savings Account Enrollment Reaches Ten Million 2Health News:Social Media Driving Leads & Sales, New Report Shows 2Health News:More than 60 percent of teachers have voice problems 2
(Date:9/2/2014)... , Sept. 2, 2014  Ameritox SM , the ... Deadly Trend: Prescription Drugs to Heroin," a research report ... heroin abuse, and examines deadly trends that have created ... here . The report is ... patients prescribed opioids. It examines five trends that distinguish ...
(Date:9/2/2014)... September 2, 2014 ... ESC-Kongress 2014 präsentierte GARFIELD-AF-Register bietet einen ... von schlaganfallgefährdeten Patienten in der klinischen ... Daten der nahezu 12.500 ... und unabhängigen Forschungsinitiative zur Untersuchung von ...
(Date:9/2/2014)... , Registry provides new insights ... and treatment satisfaction [ 1 ] ...        (Photo: http://photos.prnewswire.com/prnh/20140902/703596 ... Barcelona, Spain : Daiichi Sankyo today ... events-European Registry in Atrial Fibrillation (PREFER in AF), revealing ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... VANCOUVER, June 21, 2007 /PRNewswire-FirstCall/ - Biotech,Holdings reports ... diabetes drug its support in an overview of,diabetic ... Diabetes,Hoy, the Diabetic Federation's scientific and medical magazine ... of diabetic drugs, written by Dr. Roberto Cepeda,Gonzalez, ...
... -- Orexigen(TM),Therapeutics, Inc. , a biopharmaceutical company ... disorders with an initial focus,on obesity, today ... its lead obesity product candidate Contrave(TM) and ... fat, serum,cholesterol, and triglycerides) and insulin-resistance. The,findings ...
Cached Medicine Technology:Diabetes drug supported by Mexican Diabetes Federation 2Diabetes drug supported by Mexican Diabetes Federation 3Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 2Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 3
... with built-in bags as in a suspension file ... without contacting the ethylene glycol and without having ... ensures easy handling and maximum surface freezing concurrently ... the relatively hot air under the lid does ...
... UL Listed, CSA Certified, CE ... safely store single donor, fresh ... are standard. Cold wall refrigeration ... foamed-inplace polyurethane insulation for ultimate ...
... self-contained freezer complying with Australian Standard AS3864-1997 ... finish is grey colorbond steel with a ... to a 40-litre capacity polished stainless steel ... gasket contacting a heated top fascia. A ...
... Designed for ease of use and ... has smooth edges for comfort and is ... one-size-fits-all to a perfect fit. For hard ... a trach collar to your specifications. Don't ...
Medicine Products: